Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial

Theriva Biologics ( (TOVX) ) has shared an update.

Theriva Biologics, Inc. is actively engaging with investors and discussing their lead product candidate VCN-01, which is entering a VIRAGE Phase 2b clinical trial for metastatic pancreatic ductal adenocarcinoma (PDAC) after achieving target enrollment. VCN-01, a tumor-selective oncolytic adenovirus, has shown promise in early trials with an overall response rate of 83% and has received Fast Track and Orphan Drug Designations by the FDA. In total, 142 patients across various indications have been treated with VCN-01, evidencing its potential in cancer therapy.

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.